July 27, 2022
Guide aims to ensure future HIV mAb products are affordable and globally accessible.
Features
July 15, 2022
IAVI to participate in the 24th International AIDS Conference beginning July 29 in Montreal, Canada, and virtually
July 13, 2022
IAVI colleagues share their reflections on the importance of Pride for the global HIV response and global health research.
Jordan R. Willis, Ph.D., senior principal scientist, IAVI Neutralizing Antibody Center, Schief Lab, La Jolla, CA/Kansas City, MO
On this HVAD, our colleagues share perspectives on how an HIV vaccine can be developed with the people it seeks to benefit most.
This test sensitively quantifies diverse strains of HIV to advance vaccine and cure research.
Nkengasong was a founding leader of PEPFAR and served on IAVI’s board of directors.
March 17, 2022
HVTN, NIAID, and Moderna partner on trial of HIV Env trimers designed by IAVI's William Schief.
February 17, 2022
New TB vaccines are our best hope for a world without TB — it’s time to step up and finally make them a reality.
February 9, 2022
Using the power of social media to illuminate the urgent need for sustainable TB vaccine R&D
January 5, 2022
The archbishop advocated for the human rights of people living with HIV and tuberculosis
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
